SCHEMBL25609962

SCHEMBL25609962

CC(C)(C)NC(=O)CSc1nnnn1-c1ccc(C(=O)O)cc1

nearest known ligand 0.67

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ NPSR1 Q6W5P4 1/20 0.67
▸ HPGD P15428 2/20 0.59
▸ MEN1 O00255 4/20 0.57
▸ KMT2A Q03164 4/20 0.57
▸ POLB P06746 3/20 0.54
▸ ALDH1A1 P00352 3/20 0.54
▸ MAPK1 P28482 1/20 0.54
▸ PPARG P37231 1/20 0.54
▸ CYP1A2 P05177 1/20 0.53
▸ CYP3A4 P08684 1/20 0.53
▸ CYP2D6 P10635 1/20 0.53
▸ CYP2C19 P33261 1/20 0.53
▸ NTRK1 P04629 1/20 0.53
▸ NTRK2 Q16620 1/20 0.53
▸ NFE2 Q16621 1/20 0.53
▸ MAPT P10636 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24019617 0.87 NPSR1 (0.71) NPSR1HPGDMEN1KMT2APOLB
SCHEMBL24209903 0.85 NPSR1 (0.68) NPSR1HPGDMEN1KMT2AALDH1A1
SCHEMBL24209779 0.83 KMT2A (0.76) NPSR1HPGDMEN1KMT2AALDH1A1
SCHEMBL22009686 0.83 HPGD (0.67) NPSR1HPGDMEN1KMT2APOLB
SCHEMBL24210088 0.81 KMT2A (0.83) NPSR1HPGDMEN1KMT2AALDH1A1
SCHEMBL21951986 0.81 MAPT (0.71) NPSR1HPGDMEN1KMT2APOLB
SCHEMBL24019584 0.81 ALDH1A1 (0.70) NPSR1HPGDMEN1KMT2AALDH1A1
SCHEMBL24209668 0.81 MAPT (0.60) NPSR1HPGDMEN1KMT2APOLB
SCHEMBL24019591 0.80 SMN1; SMN2 (0.69) NPSR1HPGDMEN1KMT2APOLB
SCHEMBL24019615 0.80 NPSR1 (0.62) NPSR1HPGDMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230181535-A1 UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER FUND PROFESOR NOVOA SANTOS (ES) 2023-06-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230181535-A1 UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER XIAP, UBQLN1, MDM2 NPSR1 4628/4885HPGD 2761/4885MEN1 3372/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback